Ionis Pharmaceuticals Inc
IONS86.500USD
+3.020+3.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
13.94BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
CEOMonia (Brett P)
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
CEOMonia (Brett P)
Company Executives of Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
283.93K
+104355.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
132.88K
+22381.00%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
71.98K
+18094.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
66.25K
+17421.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
65.67K
+18195.00%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
47.87K
+17294.00%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.54K
+5047.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
283.93K
+104355.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
132.88K
+22381.00%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
71.98K
+18094.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
66.25K
+17421.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
65.67K
+18195.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.13%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Other
50.82%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.13%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Other
50.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
71.06%
Investment Advisor/Hedge Fund
19.64%
Hedge Fund
13.85%
Research Firm
2.62%
Pension Fund
0.98%
Individual Investor
0.89%
Bank and Trust
0.79%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
879
176.98M
109.27%
-8.42M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.69M
14.63%
+46.05K
+0.19%
Sep 30, 2025
Capital World Investors
17.96M
11.09%
+5.24M
+41.17%
Dec 31, 2025
The Vanguard Group, Inc.
16.44M
10.15%
-235.68K
-1.41%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
13.16M
8.12%
-2.89M
-18.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.45M
5.22%
-272.23K
-3.12%
Sep 30, 2025
Wellington Management Company, LLP
6.59M
4.07%
+243.03K
+3.83%
Sep 30, 2025
Bellevue Asset Management AG
6.24M
3.86%
-1.61M
-20.49%
Sep 30, 2025
State Street Investment Management (US)
4.39M
2.71%
-141.75K
-3.13%
Sep 30, 2025
Deep Track Capital LP
3.81M
2.35%
-1.08M
-22.15%
Sep 30, 2025
Two Sigma Investments, LP
3.65M
2.25%
-806.92K
-18.11%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
View more
Invesco Biotechnology & Genome ETF
Proportion5.24%
ARK Genomic Revolution ETF
Proportion4.11%
Virtus LifeSci Biotech Products ETF
Proportion3.34%
Franklin Genomic Advancements ETF
Proportion2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.57%
First Trust Health Care Alphadex Fund
Proportion2.47%
VanEck Morningstar SMID Moat ETF
Proportion2.38%
WisdomTree BioRevolution Fund
Proportion2.28%
State Street SPDR S&P Biotech ETF
Proportion2.28%
Capital Group US Small and Mid Cap ETF
Proportion2.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
